Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Tega Therapeutics Inc. is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is notably decentralized, involving 3 distinct examiners and 3 distinct art units. Such a distribution indicates that the company's patent applications are being reviewed across a wide array of specialized groups within the USPTO, likely reflecting a diverse range of biotechnological innovations. The use of 3 distinct art units suggests that each application faces a unique set of examination standards and administrative oversight.
The examiner MCKNIGHT, CIARA A is identified as the busiest examiner for this portfolio, currently holding 1 pending office action. Given that there are 3 pending office actions and 3 distinct examiners, the workload is spread across the involved personnel. For practitioners, this means that there is no central examiner or art unit to focus on for consistency. Each of the 3 pending office actions must be approached as an independent effort within its respective art unit. This level of variety requires a flexible prosecution strategy that can adapt to the specific nuances of the 1 busiest examiner and their colleagues.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MCKNIGHT, CIARA A | 1 | 60.8% | +38.8% |
| FRONDA, CHRISTIAN L | 1 | 82.4% | +14.2% |
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18064181 | CELLULAR GLYCOSAMINOGLYCAN COMPOSITIONS AND METHODS OF MAKING AND USING | FRONDA, CHRISTIAN L | 45d overdue |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18575016 | HEPARIN FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | MCKNIGHT, CIARA A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638760 | HEPARIN AND HEPARAN SULFATE FROM MODIFIED MAST CELLS AND METHODS OF MAKING AND USING | SABILA, MERCY HELLEN | 60d overdue |
| 18064181 | CELLULAR GLYCOSAMINOGLYCAN COMPOSITIONS AND METHODS OF MAKING AND USING | FRONDA, CHRISTIAN L | 45d overdue |
| 18575016 | HEPARIN FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | MCKNIGHT, CIARA A | — |
| Art Unit | Apps |
|---|---|
| 1656 | 1 |
| 1652 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18575016 | HEPARIN FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | MCKNIGHT, CIARA A | 1656 | §102§103Other | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18064181 | CELLULAR GLYCOSAMINOGLYCAN COMPOSITIONS AND METHODS OF MAKING AND USING | FRONDA, CHRISTIAN L | 1652 | DP | Final Rejection | 45d overdue | Pending | Dec 09, 2022 |
| 17638760 | HEPARIN AND HEPARAN SULFATE FROM MODIFIED MAST CELLS AND METHODS OF MAKING AND USING | SABILA, MERCY HELLEN | 1654 | DP | Non-Final OA | 60d overdue | Pending | Feb 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial